Type(s) of biological/targeted therapy-Bortezomib Posts on Medivizor
Navigation Menu

Type(s) of biological/targeted therapy-Bortezomib Posts on Medivizor

Evaluating the effectiveness and safety of ixazomib as maintenance therapy after bortezomib-based induction therapy in real-world patients with multiple myeloma.

Evaluating the effectiveness and safety of ixazomib as maintenance therapy after bortezomib-based induction therapy in real-world patients with multiple myeloma.

Posted by on Nov 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro) as maintenance therapy after bortezomib (Velcade)-based induction therapy in real-world patients with multiple myeloma (MM). The data showed that the outcomes of these patients in the real-world setting were good with manageable side effects. Some background...

Read More

Pomalidomide, bortezomib and dexamethasone for multiple myeloma relapsed after lenalidomide treatment

Pomalidomide, bortezomib and dexamethasone for multiple myeloma relapsed after lenalidomide treatment

Posted by on Dec 13, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the outcomes for patients with multiple myeloma (MM) who were treated with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (Decadron) after relapsing following lenalidomide (Revlimid) treatment.  This study concluded that this treatment combination was effective in...

Read More

Long-term results of RVD treatment and risk-based maintenance therapy in newly diagnosed multiple myeloma

Long-term results of RVD treatment and risk-based maintenance therapy in newly diagnosed multiple myeloma

Posted by on Jun 14, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated long-term outcomes of RVD involving lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) and risk-based maintenance therapy in patients with newly diagnosed multiple myeloma (MM). The authors found this approach to be beneficial for survival in a large group of patients. Some background RVD...

Read More

Minimal residual disease and its association with transplant success in Multiple Myeloma.

Posted by on Jan 27, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study monitored the development of minimal residual disease (MRD) after transplant for multiple myeloma (MM). The main finding was that different patterns of MRD development are associated with varying success after stem cell transplant for MM. Some background There are many treatments for MM. Patients are often cured fully by...

Read More